PRAIRIE VILLAGE, KS, Artio Medical today announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing.
Artio Medical, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million. Funds will be used to support US commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio's broad portfolio of products, including expanding the Company's engineering and manufacturing capabilities.
Artio Medical is a medical device company committed to developing innovative products for the treatment of peripheral vascular, neurovascular, and cardiovascular diseases.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about